桑志培 博士 副教授 博士/碩士生導師 海南自由貿易港高層次人才

郵箱：sangzhipei@hainanu.edu.cn

一、教育背景及工作經曆

2022.08-至今 365英国上市官网在线，副教授

2021.11-2024.11 上海中醫藥大學，博士後

2019-05至2020-06，新加坡南洋理工大學，博士後

2010-09至2015-06，四川大學華西365英国上市官网在线，碩博連讀

2006-09至2010-07，貴州醫科大學，藥學，學士

二、科研情況

目前研究方向聚焦于人工智能驅動的全新藥物設計、成藥性優化及作用機制研究”。主持國家自然科學基金、海南省自然科學基金高層次人才項目、中國博士後科學基金面上項目等10項基金，并在Acta Pharm Sin B, J Med Chem, Chinese Chem Lett, Eur J Med Chem, J Agric Food Chem等學術期刊發表論文100餘篇，其中以第一或/和通訊作者發表SCI論文62篇（中科院一區18篇，二區19篇，IF大于5的SCI論文32篇）；參與ELSEVIER出版AD領域英文專著2部；以第一發明人獲得授權發明專利27項（轉讓1項），實用新型專利5項。自2023年來，榮獲第五屆海南大學教師教學創新大賽二等獎；指導本科生以共同第一作者發表SCI論文4篇；獲批海南大學大學生創新訓練計劃項目國家級2項、省級1項；在第十二屆“挑戰杯”海南省大學生課外學術科技作品競賽中榮獲“特等獎”、“二等獎”各1項，并在第十九屆“挑戰杯”全國賽中赢得“三等獎”，等等。

三、研究領域

(1) 人工智能驅動的全新藥物設計、成藥性優化及作用機制研究

(2) 人工智能驅動的天然活性小分子的發現及活性評價

四、社會兼職

(1) 中國藥學會老年藥學專業委員會委員

(2) 《藥學學報》中、英文兩刊青年編委

(3) 《Chinese Chemical Letters》(中國化學快報）青年編委會委員

(4) 《Medicinal Plant Biology》青年編委

(5) 《Marine drugs》期刊的Guest Editor

(6) Advanced Science, Chemical Science, Acta Pharm Sin B, J Med Chem, Chinese Chem Lett, Eur J Med Chem, J Agric Food Chem等期刊雜志審稿人

五、代表性項目

(1) 國家自然科學基金，“新型腺嘌呤類PDE8高選擇性抑制劑的設計、類藥性優化及抗阿爾茨海默症作用研究”，2026.01-2029.12，主持

(2) 國家自然科學基金，“選擇性丁酰膽堿酯酶抑制劑的設計、類藥性優化及抗AD作用機制研究”，2024.01-2027.12，主持

(3) 海南省自然科學基金高層次人才項目，“丁酰膽堿酯酶選擇性抑制劑的合理設計、成藥性優化及抗阿爾茨海默症作用研究”，2024.01-2025.12，主持

(4) 海南大學科研啟動基金項目，“靶向PDE4的新型抗AD藥物研究”，2022.09-2026.12，主持

(5) 中國博士後科學基金第71批面上項目二等資助，“人羧酸酯酶2A特異性共價抑制劑的設計研發、成藥性優化及藥效學研究”，2022.01-2023.12，主持。

(6) 貴州醫科大學 省部共建藥用植物功效與利用國家重點實驗室開放課題，“杜仲中新型多肽的制備及其活性評價”，2022.01-2023.12，主持。

(7) 貴州醫科大學 化學合成藥物研發利用工程技術研究中心開放課題，“具有誘導自噬作用的cGN14細胞穿膜環肽的設計、合成及其抗AD活性研究”，2021.08-2022.07，主持。

(8) 河南省科技廳科技攻關項目，“裕丹參中新型多肽的發現及藥理活性研究”，2021.01-2022.12，主持

(9) 2020年河南省高等學校重點科研項目，“基于腦靶向的新型高選擇性BuChE抑制劑的設計、合成及其抗阿爾茨海默病活性研究”，2020.01-2021.12，主持

(10) 2019年河南省高層次人才國際化培養項目，“口服植物活性肽的研究”，2019.05-2020.06，主持

(11) 河南省自然科學基金，“基于Aβ/AChE雙靶點策略的查爾酮衍生物的設計、合成與抗阿爾茨海默病活性研究”，2016.01-2017.12，主持

(12) 2017年河南省高等學校重點科研項目計劃，“新型多靶點抑制劑的設計、合成及抗阿爾茨海默症活性研究”，2017.01-2018.12，主持

六、代表性成果（#表示為共同第一，*表示為通訊作者）

6.1 代表性論文（2020年至今）

(1) Shuheng Huang^#, Wenling Fu^#, Ma Chunhua^#, Ya Zhang, Chanchan Liang, Yuting Li, Qiyao Zhang, Haopeng Sun^*, Tao Zhang^*, Guang-Bo Ge^*, Zhipei Sang^*. Skeleton constraint-driven development of novel butyrylcholinesterase inhibitors for treating Alzheimer's disease. Nature Communications, 2025 (Under review)

(2) Zhipei Sang^#, Ya Zhang^#, Yufan Fan^#, Wenling Fu, Changhai Luan, Chanchan Liang, Hairong Zeng*, Shuheng Huang*, Guang-Bo Ge*. Artificial intelligence-driven development of novel hCES2A covalent inhibitors for treating irinotecan-triggered gut toxicity. Science Bulletin, 2025 (Under review)

(3) Zheng Li^#, Wanting Huan^#, Xingfu Liu^#, Kai Zhang, Xue Wang, Yiyou Huang, Qian Zhou, Shuheng Huang^*, Zhipei Sang^*, Haibin Luo^*. Artificial intelligence-driven discovery of pyrazolo[1,5-a]pyrimidine derivatives as novel phosphodiesterase 4 inhibitors for treating idiopathic pulmonary fibrosis. Journal of Medicinal Chemistry, 2025, Nov 18. doi: 10.1021/acs.jmedchem.5c02407. 68(6): 6252-6269.

(4) Ya Zhang^#, Yufan Fan^#, Yun-Qing Song^#, Guanghao Zhu^#, Xin-Juan Li^#, Jian Huang, Xinrui Guo, Changhai Luan, Dongning Kang, Lu Chen, Zhanping Xiao, Zhaobin Guo, Hairong Zeng^*, Dapeng Chen^*, Zhipei Sang^*, Guangbo Ge^*. Discovery of orally active and serine-targeting covalent inhibitors against hCES2A for ameliorating irinotecan-triggered gut toxicity. Acta Pharmaceutica Sinica B, 2025, 15(10):5312-5326 (Front cover article)

(5) Zhipei Sang^#, Shuheng Huang^#, Wanying Tan^#, Yujuan Ban^#, Keren Wang, Yufan Fan, Hongsong Chen, Qiyao Zhang, Chanchan Liang, Jing Mi, Yunqi Gao, Ya Zhang, Wenmin Liu, Jianta Wang, Wu Dong*, Zhenghuai Tan*, Lei Tang*, Haibin Luo. Discovery of novel butyrylcholinesterase inhibitors for treating Alzheimer’s disease. Acta Pharmaceutica Sinica B, 2025, 15(4): 2134-2155.

(6) Zhipei Sang^#, Ya Zhang^#, Yufan Fan^#, Changhai Luan, Zhengwei Liu, Qiyao Zhang, Hairong Zeng*, Yunqing Song*, Shuheng Huang*, Guangbo Ge*. AI-driven discovery of highly specific and efficacious hCES2A inhibitors for ameliorating irinotecan-triggered gut toxicity. Journal of Medicinal Chemistry, 2025, 68(6): 6252-6269.

(7) Zhipei Sang^#, Teng Xue^#, Qianru Xing^#, Qiyao Zhang, Hongsong Chen, Xue Wang, Furong Zhang, Wenling Fu, Wu Dong, Shuheng Huang^*, Yiyou Huang^*, Haibin Luo^*. Discovery of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of Alzheimer's disease: An artificial intelligence-driven synergized strategy. Chinese Chemical Letters, 2025, https://doi.org/10.1016/j.cclet.2025.111318.

(8) Qiyao Zhang#, Yuting Li#, Qishun Jin#, Zhengwei Liu#, Hongsong Chen, Jingqi Huang, Taoyi Liu, Xiaojuan Liu, Zhenghuai Tan, Shuheng Huang*, Wu Dong*, Zhipei Sang*. Artificial intelligence-driven development of natural multi-target derivatives with BuChE inhibitory activity for treating Alzheimer's disease. Chinese Chemical Letters, 2025, doi: 10.1016/j.cclet.2025.110964.

(9) Tiancheng Sun, Zhonghua Li^*, Bingyu Xiao, Jige Yang, Mengyu Han, Jiaxin Zhang, Sijia Liu, Jinlian Ma, Zhipei Sang^*, Pan Wang^*. Recent development in PDE4D-targeted inhibitors for Alzheimer's disease therapy. European Journal of Medicinal Chemistry. 2025, 302(Pt 3): 118383.

(10) Yuting Li^#, Qiyao Zhang^#, Xinxin Wang^#, Zhengwei Liu^#, Hongsong Chen, Zhenhui Su, Yidan Xu, Weichang Zhang, Yulu Du, Zhenghuai Tan, Shuheng Huang^*, Wenmin Liu^*, Zhipei Sang^*. Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD. Bioorganic Chemistry, 2025, 157: 108245.  

(11) Jia C^#, Chai J^#, Zhang S^#, Sun Y, He L, Sang Z^*, Chen D^*, Zheng X^*. The Advancements of Marine Natural Products in the Treatment of Alzheimer's Disease: A Study Based on Cell and Animal Experiments. Mar Drugs. 2025, 23(3): 91.

(12) Zhou Y^#, Sang Z^#, Xu C, Cao Z, Xiao K, Jia Q, He Y, Luo H, Huang S. MolMod: a molecular modification platform for molecular property optimization via fragment-based generation. Mol Divers. 2025 Sep 4. doi: 10.1007/s11030-025-11342-z.

(13) Du K^#, Wang X^#, Bai Y^#, Zhang X, Xue J, Li S, Xie Y^*, Sang Z^*, Tang Y^*, Wang X^*. Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection. European Journal of Medicinal Chemistry. 2024, 271: 116402.

(14) Rui Chen^#, Xinjuan Li^#, Hongsong Chen^#, Keren Wang^#, Teng Xue, Jing Mi, Yujuan Ban, Gaofeng Zhu, Yi Zhou, Wu Dong^*, Lei Tang^*, Zhipei Sang^*. Development of the “hidden” multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry. 2023, 251: 115253.

(15) Hongsong Chen^#, Jing Mi^#, Sen Li^#, Zhengwei Liu, Jing Yang, Rui Chen, Yujie Wang, Yujuan Ban, Yi Zhou^*, Wu Dong^*, Zhipei Sang^*. Design, synthesis and evaluation of quinoline-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023, 38(1): 2169682.  

(16) Zhou Yi^#, He Ying^#, Xue Teng^#, Mi Jing, Yang Jing, Wei Rongrui, Liu Wenmin^*, Ma Qinge^*, Tan Zhenghuai^*, Zhipei Sang^*. Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023, 38(1): 2231661.

(17) Wei RR, Lin QY, Adu M, Huang HL, Yan ZH, Shao F, Zhong GY, Zhang ZL^*, Sang ZP^*, Cao L^*, Ma QG^*. The sources, properties, extraction, biosynthesis, pharmacology, and application of lycopene. Food & Function. 2023, 14(22): 9974-9998.  

(18) Ma Qinge^*, Chen Jie, Chen Lihua, Wu Guang, Zhu Meining, He Nengxin, Wang Qinyuan, Sang Zhipei^*, Zhu Caiqing, Wu Yongzhong, Wei Rongrui^*. Citrus medica var. Sarcodactylus (Siebold ex Hoola van Nooten) Swingle: an insight into its botany, traditional uses, phytochemistry, and pharmacological properties. Phytochemistry Reviews. 2023, 22(5): 1-33.

(19) Ma Qinge, He Nengxin, Huang Huilian, Fu Xiaomei, Zhang Zhongli, Shu Jicheng, Wang Qinyuan, Chen Jie, Wu Guang, Zhu Meining, Sang Zhipei^*, Cao Lan^*, Wei Rongrui^*. Hippophae rhamnoides L.: A Comprehensive Review on the Botany, Traditional Uses, Phytonutrients, Health Benefits, Quality Markers, and Applications. Journal of Agricultural and Food Chemistry. 2023, 71(12): 4769-4788.

(20) Zhipei Sang^#,*, Keren Wang^#, Jianghong Dong^#, Lei Tang^*. Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress. European Journal of Medicinal Chemistry. 2022, 238: 114464.

(21) Zhipei Sang^#,*, Ping Bai^#, Yujuan Ban^#, Keren Wang^#, Anguo Wu, Jing Mi, Jiaqi Hu, Rui Xu, Gaofeng Zhu, Jianta Wang, Jiquan Zhang, Changning Wang^*, Zhenghuai Tan^*, Lei Tang^*. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer's agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies. Bioorganic Chemistry. 2022, 127: 106007.

(22) Zhipei Sang, Qing Song, Zhongcheng Cao, Yong Deng, Li Zhang^*. Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 69-85.

(23) Gaofeng Zhu^#, Ping Bai^#, Keren Wang^#, Jing Mi, Jing Yang, Jiaqi Hu, Yujuan Ban, Rui Xu, Rui Chen, Changning Wang^*, Lei Tang^*, Zhipei Sang^*. Design, synthesis, and evaluation of novel O-alkyl ferulamide derivatives as multifunctional ligands for treating Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 1375-1388.

(24) Chan Liu^#, Zhipei Sang^#, Hong Pan, Qin Wu, Yu Qiu^*, Jingshan Shi^*. A novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer's disease by dual inhibition of acetylcholinesterase and inflammation. Frontiers in Aging Neuroscience. 2022, 14: 922650.

(25) Jing Yang^#, Yi Zhou^#, Yujuan Ban^#, Jing Mi, Ying He, Xinjuan Li, Zhengwei Liu, Keren Wang, Gaofeng Zhu, Wenmin Liu, Zhenghuai Tan^*, Zhipei Sang^*. Development of naringenin-O-alkylamine derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022, 37(1): 792-816.

(26) Ma Qinge, Guan Yang, Sang Zhipei^*, Dong Jianghong, Wei Rongrui^*. Isolation and characterization of auronlignan derivatives with hepatoprotective and hypolipidemic activities from the fruits of Hippophae rhamnoides L. Food & Function. 2022, 13(14):7750-7761.

(27) Zhipei Sang^*,#, Qing Song, Zhongcheng Cao, Yong Deng, Zhenghuai Tan, Li Zhang^*. Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease. European Journal of Medicinal Chemistry. 2021, 216: 113310.

(28) Zhipei Sang^*,#, Jian Shi^#, Yi Zhou, Keren Wang, Yiyang Zhao, Qingfeng Li , Zhanpin Qiao, Anguo Wu^*, Zhenghuai Tan^*, Wenmin Liu^*. Development of genistein-O-alkylamines derivatives as multifunctional agents for the treatment of Alzheimer's disease. Bioorganic Chemistry. 2021, 107: 104602.

(29) Keren Wang^#, Jian Shi^#, Yi Zhou, Ying He, Jing Mi, Jing Yang, Shuang Liu, Xiangcheng Tang, Wenmin Liu, Zhenghuai Tan^*, Zhipei Sang^*. Design, synthesis and evaluation of cinnamic acid hybrids as multi-target-directed agents for the treatment of Alzheimer’s disease. Bioorganic Chemistry. 2021, 112：104879.

(30) Zhipei Sang^*,#, Keren Wang^#, Ping Bai^#, Anguo Wu, Jian Shi, Wenmin Liu, Gaofeng Zhu, Yiling Wang, Yu Lan, Zude Chen, Yiyang Zhao, Zhanpin Qiao, Changning Wang^*, Zhenghuai Tan^*. Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 194: 112265.

(31) Zhipei Sang^*,#, Keren Wang^#, Jian Shi, Wenmin Liu, Xinfeng Cheng, Gaofeng Zhu, Yiling Wang, Yiyang Zhao, Qiao Zhanpin, Anguo Wu^*, Zhenghuai Tan^*. The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020, 192: 112180.

(32) Zhipei Sang^*,#, Keren Wang^#, Jian Shi, Xinfeng Cheng, Gaofeng Zhu, Rongrui Wei, Qinge Ma, Lintao Yu, Yiyang Zhao, Zhenghuai Tan^*, Wenmin Liu^*. Apigenin-rivastigmine hybrids as multi-target-directed ligands for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020, 187: 111958.

6.2代表性論文（2020年之前）

(1) Sang Zhipei^*,#, Wang Keren^#, Zhang Pengfei, Shi Jian, Liu Wenmin^*, Tan Zhenghuai^*. Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 180: 238-252.

(2) Sang Zhipei^*,#, Wang Keren^#, Shi Jian, Liu Wenmin^*, Tan Zhenghuai^*. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 178: 726-739.

(3) Bai Ping^#, Wang Keren^#, Zhang Pengfei^#, Shi Jian, Cheng Xinfeng, Zhang Qi, Zheng Cheng, Yang Jian, Lu Xiaoxia^*, Sang Zhipei^*. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer’s disease. European Journal of Medicinal Chemistry, 2019, 183: 111737.

(4) Sang Zhipei^*,#, Wang Keren^#, Han Xue, Cao Mengxiao, Tan Zhenghuai^*, Liu Wenmin^*. Design, synthesis and evaluation of novel ferulic acid derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. ACS Chemical Neuroscience. 2019, 10(2): 1008-1024.

(5) Sang Zhipei^*, Pan Wanli, Wang Keren, Ma Qinge, Yu Lintao, Yang Yan, Bai Ping, Leng Chaoliang, Xu Qian, Li Xiaoqing, Tan Zhenghuai, Liu Wenmin^*. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivativesas potential multifunctional agents for the treatment of Alzheimer’s disease. European Journal of Medicinal Chemistry, 2017, 130: 379-392.

(6) Sang Zhipei^#, Qiang Xiaoming ^#, Li Yan, Xu Rui, Xu Zhongcheng, Song Qing, Wang Ting, Zhang Xiaoyu, Liu Hongyan, Tan Zhenghuai^*, Deng Yong^*. Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 135: 307-323.

(7) Zhipei Sang^#, Xiaoming Qiang^#, Yan Li^#, Wen Yuan, Qiang Liu, Wei Ang, Yikun Shi, Youfu Luo, Zhenhuai Tan^*, Yong Deng^*, Design, synthesis and evaluation of scutellarein-O-alkylamines as potent multifunctional anti-Alzheimer’s disease agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2015, 94: 348-366.

(8) Xiaoming Qiang^#, Zhipei Sang^#, Wen Yuan, Yan Li, Qiang Liu, Ping Bai, Yikun Shi, Wei Ang, Zhenhuai Tan^*, Yong Deng^*, Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 76: 314-331.

6.3 已授權代表性發明專利

(1) 桑志培; 王柯人；柳文敏；時健；程新峰；于林濤. 一種2’-羟基-3苯基苯丙酮化合物及其制備方法和用途. 2022.01.07. 中國 ZL2019106197603.

(2) 桑志培; 王柯人; 柳文敏; 于林濤; 時健; 馬倩文; 王慧娟.一種茚酮查爾酮氨基甲酸酯類化合物及其制備方法和用途. 2021.03.30. 中國ZL2019101892884.

(3) 桑志培; 王柯人; 柳文敏; 于林濤; 時健; 程新峰；馬倩文. 一種4-氨基甲酸酯-肉桂酰胺-4-苄基哌啶類化合物及其制備方法和用途. 2020.11.03. 中國ZL2019100795872.

(4) 桑志培; 王柯人; 柳文敏; 程新峰; 時健; 于林濤; 冉亞文. 一種芹菜素-O-烷基胺類化合物、制備方法和應用. 2020.06.26. 中國ZL2019100960136. (已轉讓)

七、指導本科生獲得成果獎勵（本人作為指導老師）：

7.1 指導本科生發表文章

(1) Zhipei Sang^#, Teng Xue^#, Qianru Xing^#(邢倩茹), Qiyao Zhang, Hongsong Chen, Xue Wang, Furong Zhang, Wenling Fu, Wu Dong, Shuheng Huang^*, Yiyou Huang^*, Haibin Luo^*. Discovery of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of Alzheimer's disease: An artificial intelligence-driven synergized strategy. Chinese Chemical Letters, 2025, https://doi.org/10.1016/j.cclet.2025.111318. (中科院大類一區，IF = 9.4，2022級藥學本科生邢倩茹為共同第一作者）

(2) Qiyao Zhang^#, Yuting Li^#, Qishun Jin^#(金琪順), Zhengwei Liu^#, Hongsong Chen, Jingqi Huang, Taoyi Liu, Xiaojuan Liu, Zhenghuai Tan, Shuheng Huang*, Wu Dong*, Zhipei Sang^*. Artificial intelligence-driven development of natural multi-target derivatives with BuChE inhibitory activity for treating Alzheimer's disease. Chinese Chemical Letters, 2026, 37, 110964. (中科院大類一區，IF = 9.4，2024級藥學本科生金琪順為共同第一作者)

(3) Yuting Li^#, Qiyao Zhang^#, Xinxin Wang^#(王馨莘), Zhengwei Liu^#, Hongsong Chen, Zhenhui Su, Yidan Xu, Weichang Zhang, Yulu Du, Zhenghuai Tan, Shuheng Huang^*, Wenmin Liu^*, Zhipei Sang^*. Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD. Bioorganic Chemistry, 2025, 157: 108245. (中科院大類二區，IF = 4.5，2022級藥學本科生王馨莘為共同第一作者)

(4) Zhengwei Liu^#, Xinjuan Li^#, Mengqi Huang^#(黃夢琪), Zhenhui Su, Qiyao Zhang, Yuting Li, Yi Zhou, Lintao Yu, Wenmin Liu*, Zhipei Sang*. Development of novel fluoro-substituted rivastigmine derivatives as selective AChE inhibitors for the treatment of AD. Medicinal Chemistry Research, 2024, 33(7):1-10 (中科院大類四區，IF = 3.1，2021級藥學本科生黃夢琪為共同第一作者)

7.2 指導本科生獲批項目

(1) 海南大學2025年大學生創新訓練計劃項目省級立項，“基于腦靶向的新型高選擇性BuChE抑制劑的設計、合成及抗阿爾茨海默症研究”，項目負責人：2024級藥學劉陶怡

(2) 海南大學2023年大學生創新創業計劃項目國家級立項，新型BuChE抑制劑的設計、成藥性優化及抗AD活性研究，項目編号：202310589011，項目負責人：2021級藥學蘇祯惠

(3) 海南大學2023年大學生創新創業計劃項目國家級立項，新型倒撚子素的設計、合成及其抗肺纖維化活性研究，項目編号：202310589063，項目負責人：2022級藥學邢倩茹

(4) 365英国上市官网在线2025年度本科生課外科研課題立項，項目負責人：2024級藥學劉曉娟

(5) 365英国上市官网在线2024年度本科生課外科研課題立項，項目負責人：2022級藥學王馨莘

(6) 365英国上市官网在线2023年度本科生課外科研課題立項，項目負責人：2021級藥學蘇祯惠

7.3指導本科生獲獎情況

(1) 第十九屆“挑戰杯”中國移動全國大學生課外學術科技作品競賽主體賽中榮獲“三等獎”一項，項目負責人：2024級藥學金琪順，（參與人：2022級藥學王馨莘、2022級藥學黃鏡琦、2023級藥學徐乙丹、2023級食品李家和、2023級化學王米樂、2022級藥學邢倩茹、2023級藥學楊坤坤），2025年11月，第一指導教師

(2) 第十二屆“挑戰杯”海南省大學生課外學術科技作品競賽中榮獲“特等獎”一項，項目負責人：2024級藥學金琪順，（參與人：2022級藥學黃鏡琦、2023級化學王米樂、2023級食品李家和），2025年6月，第一指導教師

(3) 第十二屆“挑戰杯”海南省大學生課外學術科技作品競賽中榮獲“二等獎”一項，項目負責人：2023級藥學徐乙丹（參與人：2022級藥學王馨莘、2023級藥學張維昌、2023級藥學杜雨露、2024級人文地理與城鄉規劃闫靖旋、2024級藥學韋珍視、2024級藥學劉陶怡），2025年6月，第一指導教師

(4) 第十五屆“挑戰杯”河南省大學生課外學術科技作品競賽中榮獲“二等獎”兩項，2021.06，第一指導教師

(5) 第十三屆“挑戰杯”河南省大學生課外學術科技作品競賽二等獎，2017.08.10，第一指導教師

(6) 第八屆“國藥工程—東富龍杯”全國大學生制藥工程設計競賽二等獎，2018.08，第二指導教師

歡迎本科生參與課題組科研課題！

歡迎有藥學、生物學、化學等相關學科背景的同學報考本課題組的博士/碩士研究生!